Genovis AB (publ.) Future Growth
Future criteria checks 3/6
Genovis AB (publ.) is forecast to grow earnings and revenue by 16.4% and 10.1% per annum respectively. EPS is expected to grow by 21.3% per annum. Return on equity is forecast to be 14.8% in 3 years.
Key information
16.4%
Earnings growth rate
21.3%
EPS growth rate
Life Sciences earnings growth | 43.1% |
Revenue growth rate | 10.1% |
Future return on equity | 14.8% |
Analyst coverage | Low |
Last updated | 12 Nov 2024 |
Recent future growth updates
Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Recent updates
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 19Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings
Aug 28Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts
Aug 23The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts
Aug 21Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Aug 12Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors
May 31This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 162 | 41 | 37 | 51 | 2 |
12/31/2025 | 152 | 36 | 28 | 32 | 3 |
12/31/2024 | 133 | 32 | 58 | 54 | 2 |
9/30/2024 | 131 | 28 | 22 | 28 | N/A |
6/30/2024 | 128 | 17 | 27 | 37 | N/A |
3/31/2024 | 128 | 31 | 27 | 39 | N/A |
12/31/2023 | 159 | 62 | 55 | 68 | N/A |
9/30/2023 | 158 | 54 | 40 | 53 | N/A |
6/30/2023 | 151 | 57 | 40 | 49 | N/A |
3/31/2023 | 142 | 42 | 42 | 47 | N/A |
12/31/2022 | 104 | 11 | -5 | -1 | N/A |
9/30/2022 | 119 | 41 | 40 | 43 | N/A |
6/30/2022 | 112 | 36 | 40 | 43 | N/A |
3/31/2022 | 111 | 36 | 37 | 41 | N/A |
12/31/2021 | 94 | 25 | 41 | 46 | N/A |
9/30/2021 | 71 | 11 | 3 | 6 | N/A |
6/30/2021 | 69 | 12 | 1 | 7 | N/A |
3/31/2021 | 65 | 9 | -12 | 9 | N/A |
12/31/2020 | 61 | 6 | -17 | 4 | N/A |
9/30/2020 | 54 | -3 | -16 | 7 | N/A |
6/30/2020 | 64 | 3 | -11 | 9 | N/A |
3/31/2020 | 60 | 6 | 4 | 9 | N/A |
12/31/2019 | 61 | 10 | 8 | 13 | N/A |
9/30/2019 | 58 | 12 | 7 | 10 | N/A |
6/30/2019 | 43 | 5 | 0 | 4 | N/A |
3/31/2019 | 40 | 1 | 2 | 3 | N/A |
12/31/2018 | 35 | -2 | -3 | -1 | N/A |
9/30/2018 | 31 | -4 | -4 | -2 | N/A |
6/30/2018 | 27 | -6 | N/A | -5 | N/A |
3/31/2018 | 24 | -7 | N/A | -9 | N/A |
12/31/2017 | 23 | -8 | N/A | -8 | N/A |
9/30/2017 | 21 | -9 | N/A | -9 | N/A |
6/30/2017 | 21 | -9 | N/A | -11 | N/A |
3/31/2017 | 20 | -14 | N/A | -15 | N/A |
12/31/2016 | 19 | -15 | N/A | -16 | N/A |
9/30/2016 | 17 | -16 | N/A | -18 | N/A |
6/30/2016 | 16 | -21 | N/A | -18 | N/A |
3/31/2016 | 14 | -18 | N/A | -14 | N/A |
12/31/2015 | 14 | -20 | N/A | -16 | N/A |
9/30/2015 | 13 | -25 | N/A | -18 | N/A |
6/30/2015 | 11 | -24 | N/A | -20 | N/A |
3/31/2015 | 10 | -23 | N/A | -21 | N/A |
12/31/2014 | 10 | -22 | N/A | -22 | N/A |
9/30/2014 | 8 | -20 | N/A | -18 | N/A |
6/30/2014 | 10 | -17 | N/A | -17 | N/A |
3/31/2014 | 11 | -16 | N/A | -14 | N/A |
12/31/2013 | 10 | -16 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GENO's forecast earnings growth (16.4% per year) is above the savings rate (1.2%).
Earnings vs Market: GENO's earnings (16.4% per year) are forecast to grow faster than the Swedish market (14.7% per year).
High Growth Earnings: GENO's earnings are forecast to grow, but not significantly.
Revenue vs Market: GENO's revenue (10.1% per year) is forecast to grow faster than the Swedish market (1.3% per year).
High Growth Revenue: GENO's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GENO's Return on Equity is forecast to be low in 3 years time (14.8%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 09:14 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genovis AB (publ.) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Daniel Albin | Danske Bank |
Simon Larsson | Danske Bank |
Josefine Persson | Nordea Markets |